Which has stronger valuation and earnings, ANVS or ALXO?

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is ANVS or ALXO more profitable?

ALX Oncology's return on equity of -124.06% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% ALX Oncology N/A -124.06% -85.57%

Does the media favor ANVS or ALXO?

In the previous week, Annovis Bio had 2 more articles in the media than ALX Oncology. MarketBeat recorded 6 mentions for Annovis Bio and 4 mentions for ALX Oncology. Annovis Bio's average media sentiment score of 0.88 beat ALX Oncology's score of -0.03 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SRZN or ANVS more profitable?

Annovis Bio has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% N/A -154.08% Annovis Bio N/A -318.08% -215.47%

Do analysts rate SIGA or ANVS?

Annovis Bio has a consensus target price of $11.67, indicating a potential upside of 526.23%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Does the media favor SIGA or ANVS?

In the previous week, Annovis Bio had 4 more articles in the media than Siga Technologies. MarketBeat recorded 6 mentions for Annovis Bio and 2 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.93 beat Annovis Bio's score of 0.88 indicating that Siga Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ANVS or IKT?

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A

Is ANVS or IKT more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Inhibikase Therapeutics N/A -41.31% -38.98%

Do analysts prefer JMAC or ANVS?

Annovis Bio has a consensus price target of $11.67, indicating a potential upside of 526.23%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger valuation & earnings, JMAC or ANVS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Annovis Bio N/A N/A -$28.85M -$1.71 N/A

Is JMAC or ANVS more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Annovis Bio N/A -318.08% -215.47%

Annovis Bio (ANVS) Competitors

$1.86 +0.00 (+0.16%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$1.83 -0.04 (-1.93%)

As of 04:59 AM Eastern

Compare

ANVS vs. ALXO, SRZN, SIGA, IKT, and JMAC

Should you buy Annovis Bio stock or one of its competitors? MarketBeat compares Annovis Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annovis Bio include ALX Oncology (ALXO), Surrozen (SRZN), Siga Technologies (SIGA), Inhibikase Therapeutics (IKT), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry.

How does Annovis Bio compare to ALX Oncology?

Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Comparatively, 21.0% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

In the previous week, Annovis Bio had 2 more articles in the media than ALX Oncology. MarketBeat recorded 6 mentions for Annovis Bio and 4 mentions for ALX Oncology. Annovis Bio's average media sentiment score of 0.88 beat ALX Oncology's score of -0.03 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annovis Bio has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

ALX Oncology's return on equity of -124.06% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
ALX Oncology	N/A	-124.06%	-85.57%

Annovis Bio presently has a consensus target price of $11.67, suggesting a potential upside of 526.23%. ALX Oncology has a consensus target price of $4.60, suggesting a potential upside of 115.96%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Annovis Bio and ALX Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does Annovis Bio compare to Surrozen?

Surrozen (NASDAQ:SRZN) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Annovis Bio has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	N/A	-154.08%
Annovis Bio	N/A	-318.08%	-215.47%

Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

In the previous week, Annovis Bio had 4 more articles in the media than Surrozen. MarketBeat recorded 6 mentions for Annovis Bio and 2 mentions for Surrozen. Annovis Bio's average media sentiment score of 0.88 beat Surrozen's score of 0.44 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Surrozen	Neutral
Annovis Bio	Positive

Annovis Bio has lower revenue, but higher earnings than Surrozen. Annovis Bio is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	35.93	-$242.03M	-$37.59	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Surrozen currently has a consensus target price of $42.00, suggesting a potential upside of 81.11%. Annovis Bio has a consensus target price of $11.67, suggesting a potential upside of 526.23%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts plainly believe Annovis Bio is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

66.6% of Surrozen shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Annovis Bio beats Surrozen on 8 of the 15 factors compared between the two stocks.

How does Annovis Bio compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Annovis Bio had 4 more articles in the media than Siga Technologies. MarketBeat recorded 6 mentions for Annovis Bio and 2 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.93 beat Annovis Bio's score of 0.88 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Siga Technologies has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Annovis Bio has a consensus target price of $11.67, indicating a potential upside of 526.23%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Siga Technologies has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$93.78M	2.75	$23.28M	$0.27	13.30
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Siga Technologies has a net margin of 21.58% compared to Annovis Bio's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Annovis Bio	N/A	-318.08%	-215.47%

Summary

Siga Technologies beats Annovis Bio on 9 of the 16 factors compared between the two stocks.

How does Annovis Bio compare to Inhibikase Therapeutics?

Annovis Bio (NYSE:ANVS) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Annovis Bio presently has a consensus price target of $11.67, suggesting a potential upside of 526.23%. Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 164.71%. Given Annovis Bio's higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Annovis Bio has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

Inhibikase Therapeutics' return on equity of -41.31% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Annovis Bio had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Annovis Bio and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.87 beat Annovis Bio's score of 0.88 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Annovis Bio	Positive
Inhibikase Therapeutics	Very Positive

Summary

Annovis Bio and Inhibikase Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Annovis Bio compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Annovis Bio (NYSE:ANVS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Maxpro Capital Acquisition's return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Annovis Bio	N/A	-318.08%	-215.47%

Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

In the previous week, Annovis Bio had 6 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 6 mentions for Annovis Bio and 0 mentions for Maxpro Capital Acquisition. Annovis Bio's average media sentiment score of 0.88 beat Maxpro Capital Acquisition's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Annovis Bio	Positive

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Annovis Bio has a consensus price target of $11.67, indicating a potential upside of 526.23%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Annovis Bio beats Maxpro Capital Acquisition on 8 of the 11 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANVS vs. The Competition

Export

Metric	Annovis Bio	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$64.55M	$3.70B	$6.89B	$23.43B
Dividend Yield	N/A	2.20%	2.68%	4.02%
P/E Ratio	-1.09	21.64	27.35	31.40
Price / Sales	N/A	218.19	507.21	170.55
Price / Cash	N/A	61.98	29.24	18.64
Price / Book	2.91	8.70	10.97	4.77
Net Income	-$28.85M	$23.83M	$3.59B	$1.06B
7 Day Performance	-5.67%	-1.11%	-0.91%	-0.39%
1 Month Performance	3.21%	8.71%	4.58%	0.05%
1 Year Performance	-31.51%	55.85%	29.78%	17.05%

Annovis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANVS Annovis Bio	3.4564 of 5 stars	$1.86 +0.2%	$11.67 +526.2%	-31.5%	$64.55M	N/A	N/A	3
ALXO ALX Oncology	2.7337 of 5 stars	$2.23 +1.6%	$4.60 +106.7%	+341.5%	$299.40M	N/A	N/A	40	Short Interest Increase Gap Down
SRZN Surrozen	2.9238 of 5 stars	$23.34 -1.4%	$42.00 +79.9%	+170.9%	$270.98M	$3.48M	N/A	80	Negative News Short Interest Increase
SIGA Siga Technologies	0.7361 of 5 stars	$3.70 -1.3%	N/A	-47.0%	$265.44M	$94.57M	13.71	40
IKT Inhibikase Therapeutics	2.31 of 5 stars	$2.00 +0.8%	$5.40 +170.7%	N/A	$263.40M	$260K	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANVS) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, SRZN, SIGA, IKT, and JMAC

How does Annovis Bio compare to ALX Oncology?

Summary

How does Annovis Bio compare to Surrozen?

Summary

How does Annovis Bio compare to Siga Technologies?

Summary

How does Annovis Bio compare to Inhibikase Therapeutics?

Summary

How does Annovis Bio compare to Maxpro Capital Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, SRZN, SIGA, IKT, and JMAC

How does Annovis Bio compare to ALX Oncology?

Do institutionals and insiders have more ownership in ANVS or ALXO?

Which has stronger valuation and earnings, ANVS or ALXO?

Does the media favor ANVS or ALXO?

Which has more volatility and risk, ANVS or ALXO?

Is ANVS or ALXO more profitable?

Do analysts prefer ANVS or ALXO?

Summary

How does Annovis Bio compare to Surrozen?

Is SRZN or ANVS more profitable?

Which has more volatility and risk, SRZN or ANVS?

Does the media favor SRZN or ANVS?

Which has preferable earnings and valuation, SRZN or ANVS?

Do analysts prefer SRZN or ANVS?

Do insiders and institutionals have more ownership in SRZN or ANVS?

Summary

How does Annovis Bio compare to Siga Technologies?

Does the media favor SIGA or ANVS?

Which has more volatility and risk, SIGA or ANVS?

Do analysts rate SIGA or ANVS?

Do institutionals & insiders believe in SIGA or ANVS?

Which has better valuation & earnings, SIGA or ANVS?

Is SIGA or ANVS more profitable?

Summary

How does Annovis Bio compare to Inhibikase Therapeutics?

Do analysts rate ANVS or IKT?

Which has more volatility & risk, ANVS or IKT?

Which has higher valuation and earnings, ANVS or IKT?

Is ANVS or IKT more profitable?

Do insiders & institutionals hold more shares of ANVS or IKT?

Does the media refer more to ANVS or IKT?

Summary

How does Annovis Bio compare to Maxpro Capital Acquisition?

Is JMAC or ANVS more profitable?

Which has more volatility & risk, JMAC or ANVS?

Does the media prefer JMAC or ANVS?

Do insiders and institutionals have more ownership in JMAC or ANVS?

Which has stronger valuation & earnings, JMAC or ANVS?

Do analysts prefer JMAC or ANVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools